UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged

After devastating regulatory setbacks last year, shares of uniQure and Replimune rose on the news that FDA Commissioner Marty Makary is leaving. But analysts don’t expect much relief, no matter who helms the agency.